GlassScriptPhysician profile
Atul K Jain
NPI 1194905711
$69,314.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $17K · 2021: $18K · 2022: $2,758 · 2023: $6,114 · 2024: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $5,543 · Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $5,543.00 |
| Food and Beverage | $926.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50,507.84 | 2019-2024 | Eylea, Eylea Hd |
| US Retina LLC | $8,931.37 | 2019-2023 | |
| Biotissue Holdings INC. | $6,997.82 | 2019-2022 | |
| Onmark, INC. | $831.26 | 2022 | |
| Genentech USA, INC. | $490.26 | 2020-2024 | Vabysmo |
| Alcon Vision LLC | $247.40 | 2019-2024 | Constellation |
| Eyepoint US, INC. | $237.38 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $213.52 | 2019-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $206.81 | 2019-2020 | |
| Heidelberg Engineering, INC. | $137.21 | 2019-2020 | |
| Astellas Pharma US INC | $128.76 | 2023-2024 | Izervay |
| Sight Sciences, INC. | $77.22 | 2019 | |
| Allergan, INC. | $61.65 | 2019-2020 | |
| Sandoz INC. | $60.92 | 2024 | Cimerli |
| Notal Vision, INC. | $52.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $45.59 | 2022-2023 | Syfovre |
| US Oncology Corporate, INC. | $43.73 | 2023 | |
| Aerie Pharmaceuticals, INC. | $23.80 | 2021 | |
| Alimera Sciences, INC. | $19.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$40,626.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.